Collins Stewart Maintains a 'Buy' on Human Genome Sciences (HGSI); Color on Additional Payor Coverage for Benlysta
Tweet
Share
E-mailGet Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
3 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Collins Stewart maintains a 'Buy' on Human Genome Sciences (NASDAQ: HGSI), PT $37.
Collins analsyt says, "While we continue to expect Benlysta to encounter the reimbursement headwinds experienced by most recent drug launches (sans a Q code), we are encouraged that in addition to Humana, additional insurance companies including, Healthnet, BCBS of SC, BCBS of Western New York, and Excellus BCBS (Upstate NY), have now agreed to cover Benlysta. We view the prior authorizations as relatively benign and are encouraged that BCBS of SC does not require prior authorization, which we believe bodes well for uptake in that region. We await additional coverage decisions from other large insurers including Aetna (NYSE: AET) and Cigna (NYSE: CI). In the near-term, we look towards EULAR (May 25-28; London) to gain additional insight into the level of physician enthusiasm and utilization expectations for Benlysta."
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $27.22 yesterday.
Collins analsyt says, "While we continue to expect Benlysta to encounter the reimbursement headwinds experienced by most recent drug launches (sans a Q code), we are encouraged that in addition to Humana, additional insurance companies including, Healthnet, BCBS of SC, BCBS of Western New York, and Excellus BCBS (Upstate NY), have now agreed to cover Benlysta. We view the prior authorizations as relatively benign and are encouraged that BCBS of SC does not require prior authorization, which we believe bodes well for uptake in that region. We await additional coverage decisions from other large insurers including Aetna (NYSE: AET) and Cigna (NYSE: CI). In the near-term, we look towards EULAR (May 25-28; London) to gain additional insight into the level of physician enthusiasm and utilization expectations for Benlysta."
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $27.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- UBS Reiterates Buy Rating on HF Sinclair (DINO)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
